Last Name


Search Results to Jonathan B. Wagner

This is a "connection" page, showing the details of why an item matched the keywords from your search.


One or more keywords matched the following properties of Wagner, Jonathan

keywords Precision Medicine
keywords Cardiovascular Therapeutic Research
preferred title Physician and Interim Division Director, Clinical Pharmacology, Toxicology & Therapeutic Innovation
research overview Jon Wagner, DO, FAAP, graduated with a Bachelor of Science degree in biochemistry with cum laude latin honors from the University of Missouri-Columbia and received his medical degree with magna cum laude honors from Kansas City University College of Osteopathic Medicine. He completed pediatrics residency at Children’s Mercy Kansas City (CMKC), followed by a dual fellowship training in pediatric cardiology and pediatric clinical pharmacology. Dr. Wagner joined Children’s Mercy Kansas City faculty in 2013. He currently holds an academic rank of Associate Professor of Pediatrics at University of Missouri-Kansas City School of Medicine. He is the division director of Clinical Pharmacology and Toxicology at CMKC. His early career research involved the impact of genetic variation and development on statin disposition during childhood. His series of pharmacogenomics driven pharmacokinetic studies involving statins has contributed to further understanding of inter-individual variability of statin response in the pediatric population. Dr. Wagner has served as a site-primary investigator for the Fontan Udenafil Exercise Longitudinal (FUEL) and Fontan Associated Liver Disease (FALD) trials sponsored by the Pediatric Heart Network (NHLBI). He is the primary investigator of the IMProving Drug dosing and Outcomes for single Ventricle patients with Fontan Associated Liver Disease (IMPROVE-FALD) research program at Children’s Mercy Kansas. He has been the director of the Cardiology Pharmacogenomics Repository (CPR) at CMKC since 2013. Dr. Wagner has previously been honored as the 2018 CMKC Department of Pediatrics Research Achievement Award and 2022 Kansas City University Alumnus of the Year Award. He holds the Matson Family Endowed Professorship in Cardiac Research at CMKC. He has received over 3 million dollars in external funding during his career from the American Heart Association, Thrasher Research Fund, and the National Institutes of Health (NIH) to support his research and fellowship programs involving pediatric cardiovascular disease and pediatric clinical pharmacology. Dr. Wagner serves on the Advisory Council on Rare Disease and Personalized Medicine for Missouri Health Net division of the Missouri Department of Social Services and was a past member of American Heart Association Kansas City Board of Directors. Dr. Wagner’s passion and research goals involve clinical integration of pharmacogenomics, pathophysiology, and precision medicine into routine cardiovascular care, but simultaneously is passionate about spending quality time with his wife (Margo) and 2 boys (Oliver and Teddy) when not busy at work.

One or more keywords matched the following items that are connected to Wagner, Jonathan

Item TypeName
Concept Embolization, Therapeutic
Concept Treatment Outcome
Concept Medication Therapy Management
Concept Molecular Targeted Therapy
Academic Article Considerations for Implementing Precision Therapeutics for Children.
Academic Article A Rare Case of Vascular Ring and Coarctation of the Aorta in Association with CHARGE Syndrome.
Academic Article Children Are Not Small Adults: Specific Findings in Statin Exposure and Response in a Growing Population.
Academic Article Results of the FUEL Trial.
Grant Statin Optimization in Pediatrics
Grant Statin Therapy in Children: Mitochondrial and Physical Function
Grant Fontan Udenafil Exercise Longitudinal (FUEL) Assessment Trial
Academic Article Genomics and Precision Medicine to Direct Statin Use in the Young.
Academic Article Critical need for pharmacologic treatment options in NAFLD: A pediatric perspective.
Academic Article Efficacy of Weight Reduction on Pediatric Nonalcoholic Fatty Liver Disease: Opportunities to Improve Treatment Outcomes Through Pharmacotherapy.
Grant Children’s Mercy Hospital Collaborative Fellowship Program in Pediatric Pharmacology
Academic Article Case report: Use of therapeutic drug monitoring and pharmacogenetic testing as opportunities to individualize care in a case of flecainide toxicity after fetal supraventricular tachycardia.
Academic Article The impact of cerebral embolization during infant cardiac surgery on neurodevelopmental outcomes at intermediate follow-up.
Academic Article Pharmacokinetic-Modeled Treatment for Neonatal Abstinence Syndrome
Academic Article Pharmacogenetics in the Treatment and Outcome of Congenital and Acquired Cardiac Disease During Childhood
Academic Article Pharmacogenetics in the Treatment and Outcome of Congenital and Acquired Cardiac Disease During Childhood. In: Anderson RH, Baker EJ, Redington A, Rigby ML, Penny D, Wernovsky G, eds. Paediatric Cardiology
Academic Article Pediatric Beta Blocker Therapy: A Comprehensive Review of Development and Genetic Variation to Guide Precision-Based Therapy in Children, Adolescents, and Young Adults.

Search Criteria
  • Precision
  • Therapeutics